ConductScience.org, home

Trial · NCT02838420

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1AlectinibNA95% Confidence Interval 20.3 to NAMonths
Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1Crizotinib11.195% Confidence Interval 9.1 to 13.0Months
Percentage of Participants With Non-serious Adverse Events and Serious Adverse EventsAlectinibSerious Adverse Events15.2Percentage of Participants
Percentage of Participants With Non-serious Adverse Events and Serious Adverse EventsCrizotinibSerious Adverse Events25.8Percentage of Participants
Percentage of Participants With Non-serious Adverse Events and Serious Adverse EventsAlectinibNon-Serious Adverse Events99.2Percentage of Participants
Percentage of Participants With Non-serious Adverse Events and Serious Adverse EventsCrizotinibNon-Serious Adverse Events100.0Percentage of Participants
Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its MetaboliteAlectinibAlectinib Baseline1590Standard Deviation 852Hours*nanogram/milliliter (hr*ng/mL)
Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its MetaboliteAlectinibM4 Baseline471Standard Deviation 243Hours*nanogram/milliliter (hr*ng/mL)
Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its MetaboliteAlectinibAlectinib Week 47760Standard Deviation 3270Hours*nanogram/milliliter (hr*ng/mL)
Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its MetaboliteAlectinibM4 Week 42890Standard Deviation 1130Hours*nanogram/milliliter (hr*ng/mL)
Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its MetaboliteAlectinibAlectinib Baseline255Standard Deviation 130Nanograms/milliliter (ng/mL)
Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its MetaboliteAlectinibM4 Baseline71.4Standard Deviation 33.5Nanograms/milliliter (ng/mL)
Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its MetaboliteAlectinibAlectinib Week 4861Standard Deviation 332Nanograms/milliliter (ng/mL)
Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its MetaboliteAlectinibM4 Week 4306Standard Deviation 111Nanograms/milliliter (ng/mL)
Time to Cmax (Tmax) of Alectinib and Its MetaboliteAlectinibAlectinib Baseline5.61Standard Deviation 3.02Hour (hr)
Time to Cmax (Tmax) of Alectinib and Its MetaboliteAlectinibM4 Baseline8.19Standard Deviation 2.30Hour (hr)
Time to Cmax (Tmax) of Alectinib and Its MetaboliteAlectinibAlectinib Week 44.30Standard Deviation 2.45Hour (hr)
Time to Cmax (Tmax) of Alectinib and Its MetaboliteAlectinibM4 Week 44.11Standard Deviation 3.06Hour (hr)

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02838420/results